ctrl K

AI Score

Unlock

Inhibikase Therapeutics I... (IKT)

AI Score

Unlock

2.30

-0.04 (-1.71%)

At close: Feb 28, 2025, 3:59 PM

2.29

-0.43%

After-hours: Feb 28, 2025, 04:19 PM EST

Inhibikase Therapeutics Income Statement

Table Mode

Year	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16
Revenue	260.5K	123.44K	3.1M	698.47K	1.12M	4.04M	2.06M	967.39K
Cost of Revenue	13.62M	6.72K	11.36M	893.8K	2.55M	3.65M	1.76M	846.39K
Gross Profit	-13.36M	116.72K	-8.26M	-195.33K	-1.43M	393.85K	305.25K	121K
Operating Income	-20.09M	-18.13M	-14.77M	-2.82M	-5.7M	-2.12M	-405.13K	-613.29K
Interest Income	1.06M	74.45K	19.92K	29.4K	24.84K	n/a	30.95K	15.45K
Pretax Income	-19.03M	-18.05M	-14.79M	-2.85M	-5.72M	-2.15M	-436.07K	-628.74K
Net Income	-19.03M	-17.91M	-14.81M	-2.88M	-5.75M	-2.15M	-436.07K	-628.74K
Selling & General & Admin	6.73M	6.22M	6.51M	2.62M	4.27M	2.52M	710.38K	734.29K
Research & Development	13.62M	12.03M	11.36M	893.8K	2.55M	3.65M	1.76M	846.39K
Other Expenses	-13.62M	-123.44K	-3.1M	-698.47K	-1.12M	n/a	n/a	n/a
Operating Expenses	6.73M	18.13M	14.77M	2.82M	5.7M	2.12M	2.47M	734.29K
Interest Expense	n/a	74.45K	19.92K	29.4K	24.84K	30.33K	n/a	n/a
Selling & Marketing Expenses	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Cost & Expenses	20.35M	18.13M	14.77M	2.82M	5.7M	2.12M	2.47M	1.58M
Income Tax	n/a	-148.91K	19.92K	29.4K	24.84K	-161.14K	-405.13K	-15.45K
Shares Outstanding (Basic)	5.33M	4.2M	3.03M	1.68M	1.72M	1.34M	1.72M	1.3M
Shares Outstanding (Diluted)	5.33M	4.2M	3.03M	1.68M	1.72M	1.34M	1.72M	1.3M
EPS (Basic)	-3.57	-4.26	-4.88	-1.72	-3.34	-1.61	-0.25	-0.48
EPS (Diluted)	-3.57	-4.26	-4.88	-1.72	-3.34	-1.61	-0.25	-0.48
EBITDA	-19.91M	-18.12M	-14.77M	-2.82M	-5.7M	n/a	n/a	n/a
Depreciation & Amortization	177.4K	6.72K	14.77M	2.82M	5.7M	2.12M	405.13K	613.29K